I
33.55
0.53 (1.61%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Immunocore Holdings plc | Bearish | Bearish |
Stockmoo Score
1.3
|
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fiera Capital Corp | 30 Jun 2024 | 875,593 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (HC Wainwright & Co., 198.06%) | Buy |
| Median | 78.00 (132.49%) | |
| Low | 66.00 (Barclays, 96.72%) | Buy |
| 66.00 (JP Morgan, 96.72%) | Buy | |
| Average | 79.80 (137.85%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 36.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Sep 2024 | 100.00 (198.06%) | Buy | 34.37 |
| 28 Aug 2024 | 100.00 (198.06%) | Buy | 36.14 | |
| Needham | 17 Sep 2024 | 78.00 (132.49%) | Buy | 34.37 |
| 09 Aug 2024 | 81.00 (141.43%) | Buy | 37.20 | |
| Barclays | 09 Aug 2024 | 66.00 (96.72%) | Buy | 37.20 |
| Oppenheimer | 09 Aug 2024 | 89.00 (165.28%) | Buy | 37.20 |
| JP Morgan | 10 Jul 2024 | 66.00 (96.72%) | Buy | 38.03 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Sep 2024 | Announcement | Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer |
| 12 Sep 2024 | Announcement | Immunocore to present at the 2024 Cantor Global Healthcare Conference |
| 29 Aug 2024 | Announcement | Immunocore announces transition of Chief Financial Officer |
| 08 Aug 2024 | Announcement | Immunocore reports second quarter financial results and provides a business update |
| 01 Aug 2024 | Announcement | Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 |
| 18 Jun 2024 | Announcement | Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |